Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA -1.60%96 PB Ratio is 9.54 as of Jul. 15, 2026, which is 10% above its 10-year median of 8.67. GuruFocus rates NSE:BETA with a GF Score™ of 96/100 and a GF Value™ of ₹1,979.51 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Beta Drugs ranks worse than 92.3% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Beta Drugs's share price is ₹2305.00. Beta Drugs's Book Value per Share for the quarter that ended in Mar. 2026 was ₹241.56. Hence, Beta Drugs's PB Ratio of today is 9.54.
Warning Sign:
Beta Drugs Ltd stock PB Ratio (=9.8) is close to 2-year high of 9.96.
The historical rank and industry rank for Beta Drugs's PB Ratio or its related term are showing as below:
NSE:BETA'
s PB Ratio Range Over the Past 10 Years
Min: 3.49 Med: 8.67 Max: 9.96
Current: 9.56
During the past 13 years, Beta Drugs's highest PB Ratio was 9.96. The lowest was 3.49. And the median was 8.67.
NSE:BETA's PB Ratio is ranked worse than 92.3% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs NSE:BETA: 9.56
During the past 12 months, Beta Drugs's average Book Value Per Share Growth Rate was 23.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 28.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 48.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Beta Drugs was 222.10% per year. The lowest was 23.40% per year. And the median was 31.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Beta Drugs PB Ratio Related Terms
Beta Drugs PB Ratio Historical Data
* Premium members only.
The historical data trend for Beta Drugs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Beta Drugs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Beta Drugs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Beta Drugs (NSE:BETA) has a PB Ratio of 9.54 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Beta Drugs and its competitors. This is 10% above median its historical median of 8.67. Over the past decade, Beta Drugs' PB Ratio has ranged from 3.49 to 9.96. According to the industry distribution chart, Beta Drugs ranks #851 out of 922 companies in the Drug Manufacturers industry, placing it in the top 92.3%.
Is Beta Drugs' PB Ratio too high?
Beta Drugs' current PB Ratio of 9.54 is 10% above median its 10-year median of 8.67. Over the past 10 years, this metric has ranged from a low of 3.49 to a high of 9.96. The Drug Manufacturers industry median PB Ratio is 1.92. Beta Drugs' value of 9.54 is 396.9% above this industry median. Based on the distribution chart, Beta Drugs ranks #851 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 96/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #851 out of 922 companies for PB Ratio. This places Beta Drugs in the lower half of its industry. The industry median PB Ratio is 1.92. Beta Drugs' value of 9.54 is 396.9% above this benchmark. Historically, Beta Drugs' own PB Ratio has ranged from 3.49 to 9.96 over the past decade. While the company's 10-year median is 8.67 vs. the industry median of 1.92, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current PB Ratio of 9.54 is 396.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current PB Ratio is 9.54, which is 10% above median its own 10-year median of 8.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,979.51, compared to a current price of ₹2,305.00 — trading 16.4% above its estimated fair value. The current PB Ratio is 9.54, which is 10% above median its 10-year median of 8.67 and 396.9% above the Drug Manufacturers industry median of 1.92. Beta Drugs' overall GF Score™ is 96/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current PB Ratio is 9.54 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,305.00 is trading 16.4% above its estimated GF Value™ of ₹1,979.51.
GuruFocus considers Beta Drugs to be Modestly Overvalued.
Key valuation signals for NSE:BETA:
PB Ratio: 9.54 (10% above median its 10-year median of 8.67)
GF Value™: ₹1,979.51 vs. price of ₹2,305.00 (16.4% above fair value)
Industry Position: 396.9% above the Drug Manufacturers median (#851 of 922)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
96GF Score
Get the complete analysis for NSE:BETA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
